42 Tissue and Liquid Biopsy–Based Comprehensive Genomic Profiling Reveal Mechanisms of Therapy Resistance and Rare Targetable Alterations in Breast Cancer

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement39th Annual Miami Breast Cancer Conference® - Abstracts
Volume 36
Issue suppl 3
Pages: 17

Background

Pathological and genomic profiling aid in the selection of targeted treatments for patients with breast cancer. However, tumors often evolve and evade therapeutic interventions. Here we examine patients profiled with tissue and liquid biopsy, to characterize the genomic landscape and identify potential vulnerabilities in the relapsed setting.


Patients and Methods

Comprehensive genomic profiling (CGP) was carried out on 29,704 patients with breast cancer profiled with tissue biopsy, 3339 with liquid biopsy (targeting up to 70 genes), and 712 patients profiled on both platforms during routine clinical care. Additionally, CGP profiles from 1430 patients tested on the most recent liquid biopsy assay (FoundationOne Liquid CDx) targeting 324 genes were also examined.


Results

Potentially actionable driver alterations were observed in both cohorts, including PIK3CA (34.0% tissue biopsy vs 33.3% liquid biopsy) and BRCA1/2 (7.1% vs 7.4%). In an analysis limited to the recent liquid biopsy assay, similar results were seen (PIK3CA 30.2% vs BRCA1/2 7.9%). Among 712 patients with paired tissue/liquid biopsies, presumably tumor-initiating truncal alterations were frequently shared. When sufficient circulating tumor DNA was present (≥10% tumor fraction), positive percent agreement was high, especially for PIK3CA (93.4%), BRCA (95.0%), and TP53 (92.8%). Acquired liquid biopsy alterations were detected in a majority of patients, with the highest frequency in estrogen receptor–positive disease (60%) and in patients with longer biopsy intervals (71% for biopsies taken >3 years apart). In addition to well-characterized resistance mutations (ESR1, NF1, RB1, and ERBB2), a diversity of potentially actionable alterations were identified in follow-up liquid biopsies, including activating mutations in PIK3CA, HRAS, NRAS, KRAS, FGFR1/2/3, and BRAF. Rare, acquired fusions included FGFR1/2 fusions in multiple patients with estrogen receptor–positive/HER2–negative disease, an ERBB2 fusion in a patient with HER2-positive disease, and an acquired RET fusion. Acquired mutations were primarily identified at a low clonal fraction and were often polyclonal, suggesting convergent evolutionary mechanisms to evade therapeutic pressure.


Conclusions

Liquid biopsy profiling provides evidence for therapeutic and selection-driven evolution, with a high frequency of shared driver alterations and a diverse set of in-pathway subclonal acquired alterations. Potentially actionable baseline and acquired alterations identified in liquid biopsies may provide insights into additional treatment options, potentially through combinatorial strategies.

Author Affiliations:

Ethan Sokol,1 Smruthy Sivakumar,2 Dexter X. Jin,2 Hanna Tukachinsky,2 Karthikeyan Murugesan,2 Dean Pavlick,2 Jeffrey S. Ross,2 Garrett M. Frampton,2 Geoffrey R. Oxnard,2 Priti S. Hegde2

1Senior Scientist, Foundation Medicine, Cambridge, MA

2Foundation Medicine, Cambridge, MA


Articles in this issue

15 COVID-19 Disease Course in Immunocompetent and Immunocompromised Patients  in a Breast Cancer Registry
15 COVID-19 Disease Course in Immunocompetent and Immunocompromised Patients in a Breast Cancer Registry
37 The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device
37 The Routine Use of Bioimpedance Spectroscopy Measurements in the Clinic as a Surrogate for Bone Mineral Content in Oncology Patients: Practical Application of the SOZO Device
18 Psychosocial Wellbeing and Health Care Resource Utilization Among Patients With Breast Cancer During COVID-19
18 Psychosocial Wellbeing and Health Care Resource Utilization Among Patients With Breast Cancer During COVID-19
43 Early Detection of Breast Cancer–Related Lymphedema: Accuracy of Indocyanine Green Lymphography Compared With Bioimpedance Spectroscopy  and Symptoms
43 Early Detection of Breast Cancer–Related Lymphedema: Accuracy of Indocyanine Green Lymphography Compared With Bioimpedance Spectroscopy and Symptoms
3 Frequency of Germline Variants in Breast Cancer Predisposing Genes: Genetic Background of Brazilian Women With Breast Cancer
3 Frequency of Germline Variants in Breast Cancer Predisposing Genes: Genetic Background of Brazilian Women With Breast Cancer
44 Implementation of a Novel Radiopaque Filament Marker at a Single Breast Cancer Surgery Center
44 Implementation of a Novel Radiopaque Filament Marker at a Single Breast Cancer Surgery Center
39TiP The PREDICT Registry: A Prospective Registry Study to Evaluate the Effect of a Predictive Assay on Treatment Decisions in Patients withDCIS Following Breast Conserving Therapy
39TiP The PREDICT Registry: A Prospective Registry Study to Evaluate the Effect of a Predictive Assay on Treatment Decisions in Patients withDCIS Following Breast Conserving Therapy
38 Clinicopathological Risk Factors, Poorly Stratified Baseline Risk, and RT Benefit Compared to DCISionRT in Patients With Ductal Carcinoma in Situ
38 Clinicopathological Risk Factors, Poorly Stratified Baseline Risk, and RT Benefit Compared to DCISionRT in Patients With Ductal Carcinoma in Situ
28 Case Series: Imaging Appearance of Non–Breast Cancer Solid Masses in the Male Breast
28 Case Series: Imaging Appearance of Non–Breast Cancer Solid Masses in the Male Breast
20 Evaluating Number, Age, and Radiographic BIRADS of Patients Visiting Mammography Unit in Baghdad, Iraq, in 2019, 2020, and 2021: A Retrospective Study
20 Evaluating Number, Age, and Radiographic BIRADS of Patients Visiting Mammography Unit in Baghdad, Iraq, in 2019, 2020, and 2021: A Retrospective Study
5 Feasibility of WF-OCT as an Adjunct to Intraoperative Specimen X-ray for Breast Conservation Surgical Specimens
5 Feasibility of WF-OCT as an Adjunct to Intraoperative Specimen X-ray for Breast Conservation Surgical Specimens
41 A Single-Centre Report on the Upgrade Rate of Complex Sclerosing Lesions of the Breast
41 A Single-Centre Report on the Upgrade Rate of Complex Sclerosing Lesions of the Breast
45 The Informed Consent Experience for Breast Cancer Surgery and Its Association With Patient Satisfaction
45 The Informed Consent Experience for Breast Cancer Surgery and Its Association With Patient Satisfaction
29 The Effect of Personality Type on Satisfaction With Information Exchange in Breast Cancer Patients
29 The Effect of Personality Type on Satisfaction With Information Exchange in Breast Cancer Patients
36 Are Positive Margins in DCIS a True Indication of Inadequate Surgery?
36 Are Positive Margins in DCIS a True Indication of Inadequate Surgery?
Related Content